Clinical Report: FDA Extends Nexplanon Use

Overview

The FDA has approved an extension of the etonogestrel implant (Nexplanon) use from three to five years for pregnancy prevention, supported by clinical trial data showing continued efficacy and no new safety concerns. This decision reflects the need for long-acting contraceptive options for diverse patient populations.

Background

The extension of Nexplanon's use duration is significant as it provides women with a reliable long-term contraceptive option, addressing the needs of those seeking effective birth control without the need for frequent interventions. The approval is based on robust clinical evidence demonstrating sustained contraceptive efficacy and safety over an extended period, which is crucial for informed clinical decision-making.

Data Highlights

Key Findings

• The FDA extended the use of Nexplanon from three to five years based on clinical trial data.
• No pregnancies occurred during years 4 and 5, resulting in a Pearl Index of 0.00.
• The study included a diverse population with a broad range of BMI values.
• No new safety findings were reported during the extended use period.
• Changes in menstrual bleeding patterns were the most common adverse reaction leading to discontinuation.
• A Risk Evaluation and Mitigation Strategy (REMS) was implemented to ensure safe insertion and removal of the implant.

Clinical Implications

Healthcare providers should be aware of the extended duration of Nexplanon use and the importance of proper insertion and removal techniques to minimize complications. The REMS program emphasizes the need for certified training for providers to ensure patient safety.

Conclusion

The FDA's approval to extend Nexplanon's use duration enhances contraceptive options for women, supported by strong clinical evidence of efficacy and safety. Ongoing education and adherence to safety protocols will be essential for optimal patient outcomes.

References

1. FDA, FDA, 2026 -- FDA Extends Nexplanon Use
2. CDC, U.S. Selected Practice Recommendations for Contraceptive Use, 2024
3. Contact Lens Spectrum — The Current State of Extended Wear
4. The ASCO Post — Extended Endocrine Therapy in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer
5. The ASCO Post — Extended Endocrine Therapy in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer
6. The ASCO Post — Extended Endocrine Therapy in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer
7. Nexplanon (etonogestrel) implant
8. Nexplanon (etonogestrel) implant
9. U.S. Selected Practice Recommendations for Contraceptive Use, 2024 | Contraception | CDC